Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 19

1.

B7-H3 and B7x are highly expressed in human prostate cancer and associated with disease spread and poor outcome.

Zang X, Thompson RH, Al-Ahmadie HA, Serio AM, Reuter VE, Eastham JA, Scardino PT, Sharma P, Allison JP.

Proc Natl Acad Sci U S A. 2007 Dec 4;104(49):19458-63. Epub 2007 Nov 27.

2.

Fine tuning the immune response through B7-H3 and B7-H4.

Yi KH, Chen L.

Immunol Rev. 2009 May;229(1):145-51. doi: 10.1111/j.1600-065X.2009.00768.x. Review.

3.

The third group of the B7-CD28 immune checkpoint family: HHLA2, TMIGD2, B7x, and B7-H3.

Janakiram M, Shah UA, Liu W, Zhao A, Schoenberg MP, Zang X.

Immunol Rev. 2017 Mar;276(1):26-39. doi: 10.1111/imr.12521. Review.

PMID:
28258693
4.

T cell coinhibition in prostate cancer: new immune evasion pathways and emerging therapeutics.

Barach YS, Lee JS, Zang X.

Trends Mol Med. 2011 Jan;17(1):47-55. doi: 10.1016/j.molmed.2010.09.006. Review.

5.

A review of B7-H3 and B7-H4 immune molecules and their role in ovarian cancer.

Fauci JM, Straughn JM Jr, Ferrone S, Buchsbaum DJ.

Gynecol Oncol. 2012 Nov;127(2):420-5. doi: 10.1016/j.ygyno.2012.08.017. Epub 2012 Aug 19. Review.

PMID:
22910694
6.

B7-h3 and its role in antitumor immunity.

Loos M, Hedderich DM, Friess H, Kleeff J.

Clin Dev Immunol. 2010;2010:683875. doi: 10.1155/2010/683875. Epub 2010 Nov 28. Review.

7.

The B7 family revisited.

Greenwald RJ, Freeman GJ, Sharpe AH.

Annu Rev Immunol. 2005;23:515-48. Review.

PMID:
15771580
8.

The B7 family of ligands and its receptors: new pathways for costimulation and inhibition of immune responses.

Carreno BM, Collins M.

Annu Rev Immunol. 2002;20:29-53. Epub 2001 Oct 4. Review.

PMID:
11861596
9.

T cell coinhibition and immunotherapy in human breast cancer.

Janakiram M, Abadi YM, Sparano JA, Zang X.

Discov Med. 2012 Oct;14(77):229-36. Review.

10.

B7-H3 and its relevance in cancer; immunological and non-immunological perspectives.

Nygren MK, Tekle C, Ingebrigtsen VA, Fodstad O.

Front Biosci (Elite Ed). 2011 Jun 1;3:989-93. Review.

PMID:
21622107
11.

Emerging mechanisms of immune regulation: the extended B7 family and regulatory T cells.

Loke P, Allison JP.

Arthritis Res Ther. 2004;6(5):208-14. Epub 2004 Aug 5. Review.

12.

Significance of B7-H1 overexpression in kidney cancer.

Thompson RH, Kwon ED.

Clin Genitourin Cancer. 2006 Dec;5(3):206-11. Review.

PMID:
17239274
13.

B7-H3-mediated tumor immunology: Friend or foe?

Wang L, Kang FB, Shan BE.

Int J Cancer. 2014 Jun 15;134(12):2764-71. doi: 10.1002/ijc.28474. Epub 2013 Sep 30. Review.

14.

[Research Progress on Co-stimulating Molecule B7-H3 in Hematological Malignancies].

Zhang W, Wang J, Ke XY.

Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2015 Dec;23(6):1758-62. doi: 10.7534/j.issn.1009-2137.2015.06.041. Review. Chinese.

PMID:
26708906
15.

B7-H3 role in the immune landscape of cancer.

Castellanos JR, Purvis IJ, Labak CM, Guda MR, Tsung AJ, Velpula KK, Asuthkar S.

Am J Clin Exp Immunol. 2017 Jun 15;6(4):66-75. eCollection 2017. Review.

16.

The inhibitory role of b7-h4 in antitumor immunity: association with cancer progression and survival.

He C, Qiao H, Jiang H, Sun X.

Clin Dev Immunol. 2011;2011:695834. doi: 10.1155/2011/695834. Epub 2011 Oct 13. Review.

17.

B7-H3 in tumors: friend or foe for tumor immunity?

Li G, Quan Y, Che F, Wang L.

Cancer Chemother Pharmacol. 2018 Jan 3. doi: 10.1007/s00280-017-3508-1. [Epub ahead of print] Review.

PMID:
29299639
18.

The CD28-B7 Family in Anti-Tumor Immunity: Emerging Concepts in Cancer Immunotherapy.

Leung J, Suh WK.

Immune Netw. 2014 Dec;14(6):265-76. doi: 10.4110/in.2014.14.6.265. Epub 2014 Dec 22. Review.

19.

The expanding repertoire of targets for immune checkpoint inhibition in bladder cancer: What lies beneath the tip of the iceberg, PD-L1.

Sankin A, Narasimhulu D, John P, Gartrell B, Schoenberg M, Zang X.

Urol Oncol. 2017 May 8. pii: S1078-1439(17)30176-X. doi: 10.1016/j.urolonc.2017.04.007. [Epub ahead of print] Review.

PMID:
28495553

Supplemental Content

Support Center